Transplant Cell Ther 2022 May 21. Epub 2022 May 21.
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, CA; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, USA.
Background: Data for outcomes after autologous hematopoietic cell transplant (auto-HCT) in DLBCL patients ≥70 years are limited OBJECTIVES: : Auto-HCT is feasible on older DLBCL patients STUDY DESIGN: : Using the CIBMTR database, we compared outcomes of auto-HCT in DLBCL patients aged 60-69 years (n=363) versus ≥70 years (n=103) between 2008 and 2019. Non-relapse mortality (NRM), relapse/progression (REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models RESULTS: : All patients received BEAM conditioning. On univariate analysis, in the 60-69 years versus ≥70 years cohorts, 100-day NRM was 3% versus 4%, 5-year REL was 47% versus 45%, 5-year PFS 40% versus 38% and 5-year OS 55% versus 41% respectively. Read More